24 results
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
with the wind down of those Legacy Assets, and costs associated with furthering our IBD pipeline candidates. Wind down costs included final patient visits
POS AM
SYRE
Spyre Therapeutics Inc.
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
associated with our Legacy Assets, costs associated with the wind down of those Legacy Assets, and costs associated with furthering our IBD pipeline … candidates. Wind down costs included final patient visits, collection and analysis of final patient data, the creation and submission of final research
POS AM
SYRE
Spyre Therapeutics Inc.
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
to clinical trial costs associated with our Legacy Assets, costs associated with the wind down of those Legacy Assets, and costs associated with furthering … our IBD pipeline candidates. Wind down costs included final patient visits, collection and analysis of final patient data, the creation and submission
CORRESP
9i0d5x il
26 Oct 23
Correspondence with SEC
12:00am
CORRESP
zmrgk98tnq5ufmt9auu8
8 Sep 23
Correspondence with SEC
12:00am
8-K
EX-2.1
3ypbj6cj 7omvebq0a
23 Jun 23
Entry into a Material Definitive Agreement
9:16am